These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 23487372)

  • 1. Mass azithromycin distribution and emerging resistance: taking a minimum harms approach.
    Malhotra-Kumar S; Goossens H
    Clin Infect Dis; 2013 Jun; 56(11):1527-9. PubMed ID: 23487372
    [No Abstract]   [Full Text] [Related]  

  • 2. Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment.
    Coles CL; Mabula K; Seidman JC; Levens J; Mkocha H; Munoz B; Mfinanga SG; West S
    Clin Infect Dis; 2013 Jun; 56(11):1519-26. PubMed ID: 23487375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae.
    Batt SL; Charalambous BM; Solomon AW; Knirsch C; Massae PA; Safari S; Sam NE; Everett D; Mabey DC; Gillespie SH
    Antimicrob Agents Chemother; 2003 Sep; 47(9):2765-9. PubMed ID: 12936971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-monthly azithromycin administration for trachoma.
    Malhotra-Kumar S; Coenen S; Klugman KP; Goossens H
    Lancet; 2009 Aug; 374(9688):449; author reply 449-50. PubMed ID: 19665641
    [No Abstract]   [Full Text] [Related]  

  • 5. Nasopharyngeal Pneumococcal Serotypes Before and After Mass Azithromycin Distributions for Trachoma.
    Keenan JD; Sahlu I; McGee L; Cevallos V; Vidal JE; Chochua S; Hawkins P; Gebre T; Tadesse Z; Emerson PM; Gaynor BD; Lietman TM; Klugman KP
    J Pediatric Infect Dis Soc; 2016 Jun; 5(2):222-6. PubMed ID: 27199475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution of azithromycin for the treatment of trachoma.
    Taylor KI; Taylor HR
    Br J Ophthalmol; 1999 Feb; 83(2):134-5. PubMed ID: 10396186
    [No Abstract]   [Full Text] [Related]  

  • 7. Solving the trachoma elimination puzzle, one piece at a time.
    Gower EW
    Lancet; 2012 Jan; 379(9811):102-3. PubMed ID: 22192487
    [No Abstract]   [Full Text] [Related]  

  • 8. Mass distribution of azithromycin for trachoma control is associated with short-term reduction in risk of acute lower respiratory infection in young children.
    Coles CL; Levens J; Seidman JC; Mkocha H; Munoz B; West S
    Pediatr Infect Dis J; 2012 Apr; 31(4):341-6. PubMed ID: 22173140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there evidence for resistance of ocular Chlamydia trachomatis to azithromycin after mass treatment for trachoma control?
    West SK; Moncada J; Munoz B; Mkocha H; Storey P; Hardick J; Gaydos CA; Quinn TC; Schachter J
    J Infect Dis; 2014 Jul; 210(1):65-71. PubMed ID: 24446528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal evaluation of three azithromycin distribution strategies for treatment of trachoma in a sub-Saharan African country, Mali.
    Schémann JF; Guinot C; Traore L; Zefack G; Dembele M; Diallo I; Traore A; Vinard P; Malvy D
    Acta Trop; 2007 Jan; 101(1):40-53. PubMed ID: 17239332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for mass antibiotic distribution for trachoma elimination.
    Gaynor BD; Yi E; Lietman T
    Int Ophthalmol Clin; 2002; 42(1):85-92. PubMed ID: 12189619
    [No Abstract]   [Full Text] [Related]  

  • 12. Eliminating blinding trachoma.
    Cook JA
    N Engl J Med; 2008 Apr; 358(17):1777-9. PubMed ID: 18434650
    [No Abstract]   [Full Text] [Related]  

  • 13. Collateral benefits arising from mass administration of azithromycin in the control of active trachoma in resource limited settings.
    Kigen G; Rotich J; Karimurio J; Rono H
    Pan Afr Med J; 2014; 19():256. PubMed ID: 25852799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical ocular antibiotics induce bacterial resistance at extraocular sites.
    Gaynor BD; Chidambaram JD; Cevallos V; Miao Y; Miller K; Jha HC; Bhatta RC; Chaudhary JS; Osaki Holm S; Whitcher JP; Holbrook KA; Fry AM; Lietman TM
    Br J Ophthalmol; 2005 Sep; 89(9):1097-9. PubMed ID: 16113356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of the use of community volunteers to distribute azithromycin for trachoma control in Ghana.
    Solomon AW; Akudibillah J; Abugri P; Hagan M; Foster A; Bailey RL; Mabey DC
    Bull World Health Organ; 2001; 79(1):8-14. PubMed ID: 11217675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete local elimination of infectious trachoma from severely affected communities after six biannual mass azithromycin distributions.
    Biebesheimer JB; House J; Hong KC; Lakew T; Alemayehu W; Zhou Z; Moncada J; Rogér A; Keenan J; Gaynor BD; Schachter J; Lietman TM
    Ophthalmology; 2009 Nov; 116(11):2047-50. PubMed ID: 19744717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Azithromycin in bronchiectasis: evidence in children?
    Bilton D
    Lancet Respir Med; 2013 Oct; 1(8):587-589. PubMed ID: 24461652
    [No Abstract]   [Full Text] [Related]  

  • 18. Trachoma.
    Fraser-Hurt N; Mabey D
    Clin Evid; 2002 Jun; (7):605-15. PubMed ID: 12230687
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae.
    Peterson J; Treadway G
    Clin Infect Dis; 1998 Jan; 26(1):248-9. PubMed ID: 9455579
    [No Abstract]   [Full Text] [Related]  

  • 20. Thinking deeper about important mass treatment trials.
    Guerrant RL; Bartelt LA; Scharf RJ
    Clin Infect Dis; 2012 Jun; 54(11):1674-5. PubMed ID: 22431805
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.